The press release references the web site. This contains the wonderfully hopeful statements that kept us happy four years ago, before the disillusionment and the 200:1 RSS. Remember when we loved reading:
++++++++++++++++++++++++
Current Development Status
- Based on successful results of a Phase 1 clinical trial, Bio-Path has initiated a Phase 2 program in AML, comprised of two clinical trials of BP1001 in combination with the first-line standard-of-care chemotherapy, low dose Ara C (LDAC):
The first has been initiated in 54 newly diagnosed AML patients who are not eligible for or who have decided to forego intensive induction therapy because of their age or fragile health.
A second study in relapsed and refractory AML patients is expected to be initiated in 2017.
- Prexigebersen has also completed a Phase 1 clinical trial in patients with CML and expects to initiate enrollment before the end of 2016 for the dose-determining segment of a Phase 2 trial of prexigebersen in combination with first-line standard-of-care for CML, dasatinib.
+++++++++++++++
WOW. THe expectations for 2016 and 2017.
WHAT HAPPENED???
WTF has been done in the four years since that "Current Status" was written?
Where have they spent all that money?
Presentations to try to get new investment are not what is needed. What is needed are presentations by credible scientists on what has been done in the last four years and what results have been obtained.
